Cargando…
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children’s Oncology Group
BACKGROUND: Ewing sarcoma (EWS) is an aggressive sarcoma with no validated molecular biomarkers. We aimed to determine the frequency of STAG2 protein loss by immunohistochemistry (IHC) and whether loss of expression is associated with outcome. METHODS: We performed a retrospective cohort study of pa...
Autores principales: | Shulman, David S., Chen, Sonja, Hall, David, Nag, Anwesha, Thorner, Aaron R., Lessnick, Stephen L., Stegmaier, Kimberly, Janeway, Katherine A., DuBois, Steven G., Krailo, Mark D., Barkauskas, Donald A., Church, Alanna J., Crompton, Brian D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726932/ https://www.ncbi.nlm.nih.gov/pubmed/36221002 http://dx.doi.org/10.1038/s41416-022-01977-2 |
Ejemplares similares
-
Detection of circulating tumour DNA is associated with
inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s
Oncology Group
por: Shulman, David S., et al.
Publicado: (2018) -
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2019) -
Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches
por: Campbell, Kevin, et al.
Publicado: (2018) -
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
por: Shulman, David S., et al.
Publicado: (2023) -
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
por: Bailey, Kelly, et al.
Publicado: (2019)